[United Therapeutics] United Therapeutics Corporation announced that the FDA has accepted the supplemental New Drug Application for nebulized Tyvaso® (treprostinil) to treat idiopathic pulmonary fibrosis, anticipating the agency's review to be complete in late April 2027.